Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study

INTRODUCTION: Diabetes is the leading cause of end-stage renal disease (ESRD). Owing to renal clearance, several antidiabetic agents cannot be used in patients with ESRD. The present protocol describes an investigator-initiated trial aiming to test safety and efficacy of treatment with the glucagon-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Idorn, Thomas, Knop, Filip K, Jørgensen, Morten, Jensen, Tonny, Resuli, Marsela, Hansen, Pernille M, Christensen, Karl B, Holst, Jens J, Hornum, Mads, Feldt-Rasmussen, Bo
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2013
Matèries:
Renal Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3641449/
https://ncbi.nlm.nih.gov/pubmed/23624993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2013-002764
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars